文献速递腹部技术与安全CT

基于去脂体重对比剂剂量与团注跟踪技术的单期门静脉期CT方案的可行性

Feasibility of a single-phase portal venous CT protocol using bolus tracking technique and lean body weight-based contrast media dose.
PubMed 文献 · Eur Radiol · 2024-08-09

这项前瞻性研究纳入105例肿瘤患者,对比基于去脂体重(LBW)的对比剂剂量(0.7 gI/kg)联合肝脏团注跟踪技术与标准方案(0.6 gI/kg总体重、70秒固定延迟)的门静脉期腹部CT图像质量,结果显示实验方案对比剂剂量中位数更低(99 mL vs 110 mL),肝及门静脉强化显著更高,肾皮质及主动脉强化无显著差异。

要点

  • 基于去脂体重的对比剂剂量联合团注跟踪技术可在降低对比剂用量的同时提高肝和门静脉强化。
  • 实验方案对比剂剂量中位数99 mL,低于标准方案的110 mL。
  • 肾皮质和主动脉强化在两种方案间无统计学显著差异。

核心结论

  • 基于去脂体重的对比剂剂量联合团注跟踪技术可实现对比剂剂量显著降低,同时肝和门静脉强化显著增高。

研究设计与样本

  • 前瞻性研究,经IRB批准并获取知情同意,2023年7月至11月随机选取105例计划行门静脉期腹部CT的肿瘤患者,实验方案为0.7 gI/kg去脂体重对比剂联合肝脏团注跟踪,对照为同一扫描仪前12个月内采用0.6 gI/kg总体重对比剂和70秒固定延迟的标准门静脉期腹部CT。

诊断标准与关键数值

  • 实验方案对比剂(350 mgI/mL)剂量中位数99 mL(IQR 81-115 mL),标准方案110 mL(IQR 100-120 mL),p<0.0001;实验方案采集延迟中位数65秒(IQR 59-73秒);实验方案归一化肝脏强化中位数1.97(IQR 1.83-2.47)vs 标准方案1.86(IQR 1.58-2.11),p<0.0001;实验方案归一化门静脉强化中位数3.43(IQR 2.73-4.04)vs 标准方案2.91(IQR 2.58-3.41),p<0.0001;肾皮质和主动脉归一化强化差异无统计学意义(p>0.05)。

临床应用与阅片要点

  • 作者指出基于去脂体重的对比剂剂量联合团注跟踪技术可克服身体组成和血流动力学的差异,提高可重复性,使CT检查更「定制化」。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the impact of the use of lean body weight (LBW)-based contrast material (CM) dose and bolus tracking technique on portal venous phase abdominal CT image quality.

MATERIALS AND METHODS: IRB-approved prospective study; informed consent was acquired. In the period July-November 2023, we randomly selected 105 oncologic patients scheduled for a portal venous phase abdominal CT to undergo our experimental protocol (i.e., 0.7 gI/Kg of LBW CM administration and bolus tracking on the liver). Included patients had performed a "standard" portal venous phase abdominal CT (i.e., 0.6 gI/Kg of total body weight (TBW) contrast material administration and 70 s fixed delay) on the same scanner within the previous 12 months. One reader evaluated CT images measuring liver, portal vein, kidney cortex, and spleen attenuation; values were normalized to paraspinal muscles.

RESULTS: Median administered contrast dose (350 mgI/mL CM) was 99 mL (IQR: 81-115 mL) using the experimental protocol and 110 mL (IQR: 100-120 mL) using the standard one (p < 0.0001). Median acquisition delay using the experimental protocol was 65" (IQR 59-73"). Median normalized hepatic enhancement was significantly higher using the experimental protocol (1.97, IQR: 1.83-2.47 vs. 1.86, IQR: 1.58-2.11; p < 0.0001). Median normalized portal vein enhancement was significantly higher using the experimental protocol (3.43, IQR: 2.73-4.04 vs. 2.91, IQR: 2.58-3.41; p < 0.0001). No statistically significant differences were found in the kidneys' cortex and aorta normalized enhancement (p > 0.05).

CONCLUSION: The combination of LBW-based CM dose administration and bolus tracking allows a significant CM dose reduction and a significant liver and portal vein enhancement increase.

CLINICAL RELEVANCE STATEMENT: Lean body weight-based contrast material (CM) dose administration and bolus tracking technique in portal venous phase CT scans overcome differences in body composition and hemodynamics, improving reproducibility. It allows a significant CM dose reduction with increased liver and portal vein enhancement.

KEY POINTS: Lean body weight (LBW)-based contrast material (CM) dosing could be superior to total body weight dosing. Portal venous phase CT with a liver bolus tracking technique improved liver and spleen enhancement with a reduced contrast dose. The combination of LBW-based CM dosing and liver bolus tracking technique enables more "customized" CT examinations.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Valletta R, Bonatti M, Vingiani V, et al. Feasibility of a single-phase portal venous CT protocol using bolus tracking technique and lean body weight-based contrast media dose. Eur Radiol. 2024. PMID: 39122853. doi:10.1007/s00330-024-11009-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。